Department of Public Health

Du er her: » Konstantin Kazankov » Publikationer » The macrophage activation marker sCD163 is associated wit...

Konstantin Kazankov

The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. / Kazankov, Konstantin; Barrera, Francisco; Møller, Holger Jon et al.
I: Liver International, Bind 36, 2016, s. 1549-1557.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Kazankov, K, Barrera, F, Møller, HJ, Rosso, C, Bugianesi, E, David, E, Ibrahim Kamal Jouness, R, Esmaili, S, Eslam, M, McLeod, D, Bibby, BM, Vilstrup, H, George, J & Grønbaek, H 2016, 'The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease', Liver International, bind 36, s. 1549-1557. https://doi.org/10.1111/liv.13150

APA

Kazankov, K., Barrera, F., Møller, H. J., Rosso, C., Bugianesi, E., David, E., Ibrahim Kamal Jouness, R., Esmaili, S., Eslam, M., McLeod, D., Bibby, B. M., Vilstrup, H., George, J., & Grønbaek, H. (2016). The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver International, 36, 1549-1557. https://doi.org/10.1111/liv.13150

CBE

Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E, Ibrahim Kamal Jouness R, Esmaili S, Eslam M, McLeod D, et al. 2016. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver International. 36:1549-1557. https://doi.org/10.1111/liv.13150

MLA

Kazankov, Konstantin et al. "The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease". Liver International. 2016, 36. 1549-1557. https://doi.org/10.1111/liv.13150

Vancouver

Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver International. 2016;36:1549-1557. Epub 2016 apr. 22. doi: 10.1111/liv.13150

Author

Kazankov, Konstantin ; Barrera, Francisco ; Møller, Holger Jon et al. / The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. I: Liver International. 2016 ; Bind 36. s. 1549-1557.

Bibtex

@article{0a167b5a499c482888e11135fc42b526,
title = "The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease",
abstract = "BACKGROUND AND AIMS: Macrophage activation plays a key pathogenic role in experimental non-alcoholic fatty liver disease (NAFLD) and contributes to the progression of steatohepatitis (NASH) and fibrosis. We studied macrophage activation in human NAFLD by measuring soluble (s)CD163, a specific macrophage activation marker, hypothesizing that sCD163 would be associated with the patients' morphological disease grade. Further, we investigated an association between sCD163 and the apoptosis marker cytokeratin-18 (CK-18) to explore a link between macrophage activation and apoptosis.METHODS: sCD163 associations with biochemical and histological measures of NAFLD were investigated in two independent cohorts of 157 Australian and 174 Italian NAFLD patients with liver biopsies graded for NAFLD severity, steatosis, and fibrosis. sCD163 and CK-18 were measured by ELISA.RESULTS: In both cohorts sCD163 increased in parallel with the patients' morphological disease grading, being independently associated with the Kleiner fibrosis score (p<0.001). A high sCD163 predicted advanced fibrosis (F≥3; Australian cohort: AUROC 0.77 (95% CI: 0.76-0.87), Italian cohort: 0.80 (95% CI: 0.72-0.88)). In both groups, sCD163 was independently associated with CK-18 (p<0.001).CONCLUSION: Soluble CD163 reflecting macrophage activation is associated with morphological features of NAFLD suggesting their involvement in the pathogenesis of NAFLD, NASH and particularly fibrosis. An independent association between sCD163 and cytokeratin-18 suggests that apoptosis may contribute to macrophage activation in NAFLD/NASH. This article is protected by copyright. All rights reserved.",
keywords = "non-alcoholic steatohepatitis, biomarker, cirrhosis, liver fibrosis, macrophages",
author = "Konstantin Kazankov and Francisco Barrera and M{\o}ller, {Holger Jon} and Chiara Rosso and Elisabetta Bugianesi and Ezio David and {Ibrahim Kamal Jouness}, Ramy and Saeed Esmaili and Mohammed Eslam and Duncan McLeod and Bibby, {Bo Martin} and Hendrik Vilstrup and Jacob George and Henning Gr{\o}nbaek",
note = "This article is protected by copyright. All rights reserved.",
year = "2016",
doi = "10.1111/liv.13150",
language = "English",
volume = "36",
pages = "1549--1557",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd.",

}

RIS

TY - JOUR

T1 - The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease

AU - Kazankov, Konstantin

AU - Barrera, Francisco

AU - Møller, Holger Jon

AU - Rosso, Chiara

AU - Bugianesi, Elisabetta

AU - David, Ezio

AU - Ibrahim Kamal Jouness, Ramy

AU - Esmaili, Saeed

AU - Eslam, Mohammed

AU - McLeod, Duncan

AU - Bibby, Bo Martin

AU - Vilstrup, Hendrik

AU - George, Jacob

AU - Grønbaek, Henning

N1 - This article is protected by copyright. All rights reserved.

PY - 2016

Y1 - 2016

N2 - BACKGROUND AND AIMS: Macrophage activation plays a key pathogenic role in experimental non-alcoholic fatty liver disease (NAFLD) and contributes to the progression of steatohepatitis (NASH) and fibrosis. We studied macrophage activation in human NAFLD by measuring soluble (s)CD163, a specific macrophage activation marker, hypothesizing that sCD163 would be associated with the patients' morphological disease grade. Further, we investigated an association between sCD163 and the apoptosis marker cytokeratin-18 (CK-18) to explore a link between macrophage activation and apoptosis.METHODS: sCD163 associations with biochemical and histological measures of NAFLD were investigated in two independent cohorts of 157 Australian and 174 Italian NAFLD patients with liver biopsies graded for NAFLD severity, steatosis, and fibrosis. sCD163 and CK-18 were measured by ELISA.RESULTS: In both cohorts sCD163 increased in parallel with the patients' morphological disease grading, being independently associated with the Kleiner fibrosis score (p<0.001). A high sCD163 predicted advanced fibrosis (F≥3; Australian cohort: AUROC 0.77 (95% CI: 0.76-0.87), Italian cohort: 0.80 (95% CI: 0.72-0.88)). In both groups, sCD163 was independently associated with CK-18 (p<0.001).CONCLUSION: Soluble CD163 reflecting macrophage activation is associated with morphological features of NAFLD suggesting their involvement in the pathogenesis of NAFLD, NASH and particularly fibrosis. An independent association between sCD163 and cytokeratin-18 suggests that apoptosis may contribute to macrophage activation in NAFLD/NASH. This article is protected by copyright. All rights reserved.

AB - BACKGROUND AND AIMS: Macrophage activation plays a key pathogenic role in experimental non-alcoholic fatty liver disease (NAFLD) and contributes to the progression of steatohepatitis (NASH) and fibrosis. We studied macrophage activation in human NAFLD by measuring soluble (s)CD163, a specific macrophage activation marker, hypothesizing that sCD163 would be associated with the patients' morphological disease grade. Further, we investigated an association between sCD163 and the apoptosis marker cytokeratin-18 (CK-18) to explore a link between macrophage activation and apoptosis.METHODS: sCD163 associations with biochemical and histological measures of NAFLD were investigated in two independent cohorts of 157 Australian and 174 Italian NAFLD patients with liver biopsies graded for NAFLD severity, steatosis, and fibrosis. sCD163 and CK-18 were measured by ELISA.RESULTS: In both cohorts sCD163 increased in parallel with the patients' morphological disease grading, being independently associated with the Kleiner fibrosis score (p<0.001). A high sCD163 predicted advanced fibrosis (F≥3; Australian cohort: AUROC 0.77 (95% CI: 0.76-0.87), Italian cohort: 0.80 (95% CI: 0.72-0.88)). In both groups, sCD163 was independently associated with CK-18 (p<0.001).CONCLUSION: Soluble CD163 reflecting macrophage activation is associated with morphological features of NAFLD suggesting their involvement in the pathogenesis of NAFLD, NASH and particularly fibrosis. An independent association between sCD163 and cytokeratin-18 suggests that apoptosis may contribute to macrophage activation in NAFLD/NASH. This article is protected by copyright. All rights reserved.

KW - non-alcoholic steatohepatitis

KW - biomarker

KW - cirrhosis

KW - liver fibrosis

KW - macrophages

U2 - 10.1111/liv.13150

DO - 10.1111/liv.13150

M3 - Journal article

C2 - 27102725

VL - 36

SP - 1549

EP - 1557

JO - Liver International

JF - Liver International

SN - 1478-3223

ER -